OakChart

Xencor Inc

XNCRHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 3:59 PM ET

39.97+0.58 (1.47%)
2026-11-12 05:07 CET
Market cap
2,999.34 USD m
Revenue, TTM
200.49 USD m
Net income, TTM
-117.86 USD m
Free cash flow, TTM
-176.45 USD m
EPS diluted, TTM
-1.59
P/E
-
Compare

Price

XNCR against its 20, 50 and 200-day averages
2050200beat
10.0020.0030.0040.004.5M8.9MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26XNCRclose 39.9720-day 30.1250-day 26.91200-day 17.8539.9752w low

1.6% under the 52-week high of 40.60 on 11 Nov 2026. 52-week low 10.38 on 19 May 2026. Last 15 sessions, 66.3% high to low

Volume 0.71× normal · the line is the 50-bar volume average

Profile

XNCR
52-week range, 100% of the way up
10.3840.08

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Pasadena, CA.

IndexRUT
Employees260
IPODec 03, 2013
Beta0.73
ATR, 14d2.05
Rel volume0.71
Short float18.26%
Insider own5.87%
Inst own109.68%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap3.00B
Enterprise Value2.75B
Income-117.86M
Sales200.49M
Book/sh7.50
Cash/sh5.40
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees260
IPODec 03, 2013

Ratios

P/E-
Forward P/E-
PEG-
P/S14.96
P/B5.33
P/C7.40
P/FCF-
EV/EBITDA-
EV/Sales13.74
Quick Ratio6.54
Current Ratio6.54
Debt/Eq0.29
LT Debt/Eq0.24
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.59
EPS next Y-3.62
EPS next Q-0.79
EPS this Y-96.62%
EPS next Y-48.47%
EPS next 5Y-
EPS past 3/5Y-10.21% -0.43%
Sales past 3/5Y-8.62% 0.47%
EPS Y/Y TTM11.51%
Sales Y/Y TTM33.55%
EPS Q/Q721.36%
Sales Q/Q454.88%
EarningsNov 04 AMC
EPS/Sales Surpr.249.66% 84.96%

Ownership

Insider Own5.87%
Insider Trans-0.69%
Inst Own109.68%
Inst Trans-5.28%
ROA-14.38%
ROE-19.88%
ROIC-17.00%
Gross Margin95.10%
Oper. Margin-72.67%
Profit Margin-58.79%
SMA2032.70%
SMA5048.54%
SMA200123.89%
Trades-

Technical

Shs Outstand74.76M
Shs Float70.63M
Short Float18.26%
Short Ratio8.28
Short Interest12.90M
52W High40.08 -0.27%
52W Low10.38 285.25%
Volatility6.27% 6.73%
ATR (14)2.05
RSI (14)82.30
Beta0.73
Rel Volume0.71
Avg Volume1.56M
Volume1,103,437

Performance

Perf Week14.10%
Perf Month69.94%
Perf Quarter73.86%
Perf Half Y222.86%
Perf YTD161.07%
Perf Year168.80%
Perf 3Y134.29%
Perf 5Y1.01%
Perf 10Y76.00%
Recom1.36
Target Price42.50
Prev Close39.39
Price39.97
Change %1.47%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 30, 2026ResumedWWells FargoOverweight$55+37.6%
Mar 24, 2026DowngradeJJP MorganOverweight → Neutral$13-67.5%
Nov 24, 2025InitiatedTTruistBuy
Oct 29, 2025UpgradeBBarclaysUnderweight → Overweight$23-42.5%
Sep 17, 2025ResumedBBarclaysUnderweight$6-85.0%
Sep 03, 2025DowngradeBBofA SecuritiesBuy → Neutral$12-70.0%
Apr 21, 2025InitiatedWWilliam BlairOutperform
Dec 12, 2024InitiatedWWells FargoOverweight$37-7.4%
Dec 02, 2024UpgradePPiper SandlerNeutral → Overweight$20 → $30-24.9%
Apr 16, 2024ReiteratedBBTIG ResearchBuy$56 → $38-4.9%

Peers

Mkt cap
TickerCompanyMkt cap
JANXJanux Therapeutics Inc758.06M
ZYMEZymeworks BC Inc2.02B
MGNXMacrogenics Inc147.78M
CGEMCullinan Therapeutics Inc730.42M
GMABGenmab ADR33.13B
IMNMImmunome Inc2.25B
ABCLAbCellera Biologics Inc3.90B
INBXInhibrx Biosciences Inc1.33B
CTMXCytomX Therapeutics Inc464.35M
ADAGAdagene Inc ADR143.01M

Insider trading

latest 14 of 42
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
RANIERI RICHARD JDirectorNov 10 '26Proposed Sale39.2581,2523,189,425Nov 10 04:13 PM
Feigal EllenDirectorJun 18 '26Sale13.066,84389,37012,340Jun 22 04:01 PM
Feigal EllenDirectorJun 18 '26Proposed Sale13.066,84389,370Jun 18 09:38 AM
GORMAN KEVIN CHARLESDirectorJun 15 '26Sale12.317,52792,65711,378Jun 17 04:02 PM
GUSTAFSON KURT ADirectorJun 15 '26Sale12.315,47467,38514,709Jun 17 04:01 PM
RANIERI RICHARD JDirectorJun 15 '26Sale12.315,47467,38513,709Jun 17 04:01 PM
Montgomery Alan BruceDirectorJun 15 '26Sale12.315,06462,33815,547Jun 17 04:01 PM
Montgomery Alan BruceDirectorJun 15 '26Proposed Sale12.315,06462,338Jun 15 11:36 AM
RANIERI RICHARD JDirectorJun 15 '26Proposed Sale12.315,47467,385Jun 15 10:57 AM
GUSTAFSON KURT ADirectorJun 15 '26Proposed Sale12.315,47467,385Jun 15 10:44 AM
GORMAN KEVIN CHARLESDirectorJun 15 '26Proposed Sale12.317,52792,657Jun 15 09:44 AM
Cornelissen Bart JanSR. VICE PRESIDENT & CFOApr 10 '26Sale12.293,49942,99075,898Apr 13 04:01 PM
Cornelissen Bart JanOfficerApr 10 '26Proposed Sale12.293,49942,990Apr 10 03:16 PM
Desjarlais John RSR. VICE PRESIDENT & CSOMar 05 '26Sale11.254,11846,309266,333Mar 09 04:07 PM

Held by

AUM
TickerCompanyAUM
IJRiShares Core S&P Small-Cap ETFAUM: 106.27B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
SPSMState Street SPDR Portfolio S&P 600TM Small Cap ETFAUM: 16.06B
IJSiShares S&P Small-Cap 600 Value ETFAUM: 7.74B
IBBiShares Biotechnology ETFAUM: 11.36B
VXFVanguard Extended Market Index ETFAUM: 30.47B
XSMOInvesco S&P SmallCap Momentum ETFAUM: 2.74B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-040.500-0.3340.500116.5263.0013
2026Q22026-08-05-0.290-0.802-0.28651.2218.8913
2026Q12026-05-06-1.710-0.829-1.7134.5227.8613
2025Q42026-02-25-0.090-0.601-0.08928.2429.9613
2025Q32025-11-05-0.080-0.689-0.08121.0028.7112
2025Q22025-08-06-0.410-0.720-0.41543.6122.5911
2025Q12025-05-07-0.660-0.583-0.65732.7322.3211
2024Q42025-02-27-0.620-0.784-0.62352.7920.4311
2024Q32024-11-06-0.710-0.981-0.72310.7114.5910
2024Q22024-08-05-1.070-0.831-1.09216.9620.0011
2024Q12024-05-09-1.110-0.830-1.20012.8123.0712
2023Q42024-02-27-0.310-0.106-0.42944.6977.6313
2023Q32023-11-07-0.400-0.726-0.40059.1630.0114
2023Q22023-08-03-0.370-0.797-0.36745.5226.2514
2023Q12023-05-08-1.020-0.663-1.01718.9628.7214
2022Q42023-02-23-0.200-0.788-0.20121.6120.0715

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY0.4600.4070.460156.7163.18
2020FY-1.210-1.407-1.212122.69110.09
2021FY1.3700.2431.366275.11194.55
2022FY-0.930-1.509-0.925164.58164.55
2023FY-2.080-1.903-2.200168.34197.61
2024FY-3.580-3.662-3.577110.4961.23
2025FY-1.240-1.768-1.240125.58128.83
2026FY--2.438--187.59
2027FY--3.620--116.41
2028FY--3.818--100.3
2029FY--3.012--188.55
2030FY--1.090--434

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-09134529.173.1280.40
2026Q4S2026-11-06134529.163.1280.40
2026Q4S2026-11-05134529.163.1280.40
2026Q4S2026-11-04131130.093.1280.03
2026Q4S2026-10-23131130.093.1280.03
2026Q4S2026-10-21130128.403.1280.03
2026Q4S2026-10-20130228.403.1280.03
2026Q4S2026-09-29132628.403.1280.03
2026Q4S2026-09-24133628.403.1280.03
2026Q4S2026-09-02133628.403.1280.03
2026Q4S2026-08-07133530.133.5080.03
2026Q4S2026-08-06133431.393.5080.03
2026Q4S2026-07-29132128.453.5079.49
2026Q4S2026-07-23132128.453.5079.49

Estimate history

EPS, annual-0.822-1.3050.46-1.2121.366-0.925-2.2-3.577-1.238-1.5856
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.723-0.623-0.657-0.415-0.081-0.089-1.713-0.2860.503
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual46.1540.603156.7122.694275.111164.579174.615110.493125.576200.49
Period201720182019202020212022202320242025TTM
Sales, quarterly17.79652.79332.73243.60820.99928.2374.51651.221116.52
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual47.00256.2856.90257.87359.35659.99860.99870.25671.87274.763
Period201720182019202020212022202320242025MRQ
Shares, quarterly69.96370.25671.13671.29771.34371.87274.06474.32974.763
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue200.49125.58110.49174.62164.58275.11122.69156.7040.60
Cost of Goods Sold Incl. D&A9.8210.5112.1111.508.807.49---
Gross Profit190.67115.0698.39163.12155.78267.62---
Selling, General and Administrative Excl. Other336.37292.57276.79295.48236.75222.95193.20138.38116.72
Research and Development285.69239.43227.69253.60199.56192.51169.80118.5997.50
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-145.69-177.50-178.41-132.36-80.9744.67-76.3014.02-79.37
Interest Expense23.5231.9336.646.180.000.000.000.000.00
Unusual Expense-8.04-77.9619.150.00-21.93-20.090.500.20-
Net Income Before Taxes-115.56-89.63-234.92-119.63-54.5182.63-69.3327.19-70.41
Income Taxes2.302.501.6213.660.670.000.000.310.00
Consolidated Net Income-117.86-92.14-236.54-133.30-55.1882.63-69.3326.88-70.41
Net Income From Continuing Operations-117.86-91.92-232.62-133.13-55.1882.63-69.3326.88-70.41
Net Income-117.86-91.92-232.62-133.13-55.1882.63-69.3326.88-70.41
EPS (Recurring)-1.58-1.97-3.37-2.20-1.181.13-1.210.46-1.31
EPS (Basic, Before Extraordinaries)-1.57-1.24-3.58-2.20-0.931.42-1.210.48-1.31
EPS (Diluted)-1.59-1.24-3.58-2.20-0.931.37-1.210.46-1.31
EBITDA-135.87-166.99-166.30-120.86-72.1752.16-70.5018.32-76.12
Non-Operating Income (Expense)45.6241.84-0.7218.914.5317.887.4613.368.96
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense30.3134.1542.0942.4748.9136.9831.6223.2516.23
Price To Earnings Ratio----54.4529.82-77.98-
Price To Sales Ratio9.759.0513.537.369.448.8220.3412.8348.04
Gross Margin95.1091.6389.0493.4294.6597.28---
Operating Margin-72.67-141.35-161.47-75.80-49.2016.24-62.188.95-195.48
Net Margin-58.79-73.20-210.53-76.24-33.5330.04-56.5117.15-173.41
Shares Outstanding74.7671.8770.2661.0060.0059.3657.8756.9056.28
Market Capitalization2,999.342,999.341,608.191,292.381,560.422,346.282,506.771,950.642,033.42

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue116.5251.224.5228.2421.0043.6132.7352.79
Cost of Goods Sold Incl. D&A2.242.442.572.582.602.652.692.99
Gross Profit114.2848.781.9525.6618.4040.9530.0449.80
Selling, General and Administrative Excl. Other91.4285.8579.8179.2965.9274.1373.2262.98
Research and Development84.3071.9164.6764.8254.3761.6658.5851.06
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income22.86-37.07-77.86-53.63-47.52-33.17-43.18-13.18
Interest Expense4.117.354.707.357.678.248.668.66
Unusual Expense-1.59-17.2751.93-41.11-42.65-3.113.92-3.01
Net Income Before Taxes39.26-21.92-128.64-4.27-6.03-31.07-48.27-44.58
Income Taxes-0.17-0.190.282.390.00-0.250.371.62
Consolidated Net Income39.44-21.73-128.92-6.65-6.03-30.82-48.63-46.20
Net Income From Continuing Operations39.44-21.73-128.92-6.65-6.03-30.82-48.42-45.55
Net Income39.44-21.73-128.92-6.65-6.03-30.82-48.42-45.55
EPS (Recurring)0.49-0.45-1.23-0.48-0.48-0.44-0.62-0.65
EPS (Basic, Before Extraordinaries)0.52-0.29-1.71-0.09-0.08-0.41-0.66-0.62
EPS (Diluted)0.50-0.29-1.71-0.09-0.08-0.41-0.66-0.62
EBITDA25.10-34.63-75.30-51.05-44.92-30.52-40.49-10.18
Non-Operating Income (Expense)18.925.235.8615.616.517.237.51-25.75
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.457.267.558.057.978.489.651.14
Price To Sales Ratio9.7511.639.329.095.813.976.1615.22
Gross Margin98.0895.2443.1690.8787.6293.9291.7794.33
Operating Margin19.62-72.37-1,724.14-189.92-226.29-76.07-131.93-24.96
Net Margin33.84-42.42-2,854.65-23.56-28.70-70.69-147.92-86.29
Shares Outstanding74.7674.3374.0671.8771.3471.3071.1470.26
Market Capitalization2,999.341,193.68884.461,093.29836.62559.40749.711,608.19

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments547.73497.77593.73621.76333.31601.60527.08292.06222.43
Short Term Receivables29.3060.8523.7430.3067.1825.3424.7813.292.84
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets22.7918.9818.1423.2823.8810.736.5510.385.61
Total Current Assets599.82577.60635.60675.34424.37637.67558.40315.73230.88
Net Property, Plant & Equipment90.9098.14100.1293.6059.9732.2825.1811.817.09
Total Investments and Advances175.89257.22210.1058.21331.7317.1071.53236.11139.20
Long-Term Note Receivable---0.00---0.000.10
Intangible Assets8.3818.4818.6618.5016.4915.9814.4211.9711.15
Other Assets0.500.500.650.615.650.210.711.111.79
Total Assets875.50951.95965.13846.27838.21703.24670.25576.73390.20
Short Term Debt Incl. Current Port. of LT Debt46.5351.4631.154.710.001.892.170.000.00
Accounts Payable10.8316.7613.9110.0914.008.9510.193.806.87
Income Tax Payable3.590.005.29----0.000.16
Other Current Liabilities34.9619.2223.5649.0556.74110.2254.2050.0665.62
Total Current Liabilities95.9187.4373.9263.8470.74121.0666.5653.8572.65
Long Term Debt141.22180.50220.8054.9333.979.748.560.000.00
Provision for Risks Charges0.009.998.340.000.000.000.000.000.00
Other Liabilities2.780.000.000.000.000.001.931.201.09
Total Liabilities239.91277.92303.05118.77104.71130.8077.0555.0573.74
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity635.59677.61661.75727.50733.50572.44593.20521.68316.46
Total Shareholders Equity635.59677.61661.75727.50733.50572.44593.20521.68316.46
Accumulated Minority Interest0.00-3.580.340.000.000.000.000.000.00
Total Equity635.59674.03662.09727.50733.50572.44593.20521.68316.46
Total Liabilities & Stockholders Equity875.50951.95965.13846.27838.21703.24670.25576.73390.20
Book Value Per Share8.849.6410.8512.1312.369.8910.429.276.73
Tangible Book Value Per Share8.739.3810.5411.8212.089.6210.179.066.50
Full-Time Employees260250280281254202166156114
Price to Book Ratio5.332.221.932.153.254.413.303.903.54
Return on Assets-10.06-24.27-14.70-6.5510.72-10.104.31-14.56-9.40
Return on Equity-14.00-34.74-19.17-7.5512.65-11.904.82-17.52-12.21
Return on Invested Capital-11.83-27.11-15.09-7.0510.77-11.914.47-13.50-12.16
Quick Ratio6.256.618.6010.586.005.278.395.863.18
Current Ratio6.256.618.6010.586.005.278.395.863.18

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-117.86-92.14-236.54-133.30-55.1882.63-69.3326.88-70.41
Depreciation9.8210.5112.1111.508.807.495.794.303.25
Other Funds (Non Cash)-17.85-100.9462.6524.7422.00-4.3710.3627.7620.57
Funds from Operations-125.89-182.57-161.79-97.06-24.3885.75-53.1858.93-46.59
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-46.4647.45-40.4019.1348.87-102.6048.185.44-33.17
Income Taxes Payable-3.59-4.4813.63--0.000.00-0.16
Cash from Operating Activities-172.35-135.12-202.19-77.9324.48-16.85-5.0064.37-79.76
Capital Expenditures-4.09-3.15-9.51-21.25-43.40-15.98-13.77-11.04-9.15
Net Assets From Acquisitions1.730.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.500.000.020.000.000.01
Purchase or Sale of Investments194.39143.131.64-89.81-81.32-24.45113.96-39.93-155.72
Purchase of Investments-255.26-298.89-595.05-782.90-387.93-509.60-643.66-496.86-377.84
Sale Or Maturity of Investments449.65442.03596.69693.09306.61485.15757.62456.92222.12
Other Uses0.000.000.000.000.00-5.840.000.000.00
Other Sources0.000.000.000.005.000.000.000.000.09
Cash from Investing Activities192.02139.99-7.87-110.56-119.72-46.25100.19-50.97-164.77
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock18.299.96197.155.395.7043.0418.0410.66254.24
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock18.299.96197.155.395.7043.0418.0410.66254.24
Proceedsfrom Stock Options0.330.00-12.080.000.0028.920.000.00245.50
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-1.73-1.730.00183.330.000.000.000.000.00
Other Financing Activities Uses-1.73-1.730.000.000.000.000.000.000.00
Cash from Financing Activities16.578.23197.15188.725.7043.0418.0410.66254.24
Net Change in Cash36.2413.10-12.910.23-89.54-20.06113.2324.079.72
Free Cash Flow-176.45-138.27-208.28-96.37-14.01-30.15-15.5457.02-86.97
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow-------35.26-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments405.08456.45444.95547.73471.04443.86
Short Term Receivables64.8442.2312.0029.3021.8047.55
Inventories0.000.000.000.000.000.00
Other Current Assets28.7424.5325.9022.7925.5921.73
Total Current Assets498.66523.21482.86599.82518.44513.15
Net Property, Plant & Equipment85.5286.0088.3190.9092.9693.84
Total Investments and Advances180.77108.73157.58175.89247.45260.69
Intangible Assets5.056.527.608.389.4711.25
Other Assets0.500.500.500.500.500.50
Total Assets770.50724.96736.85875.50868.81879.42
Short Term Debt Incl. Current Port. of LT Debt27.4631.2730.4446.5349.3053.67
Accounts Payable6.6512.657.9210.839.0818.53
Income Tax Payable1.151.500.843.59--
Other Current Liabilities41.0136.4534.2534.9628.1123.88
Total Current Liabilities76.2781.8673.4695.9186.4896.08
Long Term Debt132.77138.83144.72141.22153.11159.29
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities1.031.033.042.783.903.70
Total Liabilities210.07221.73221.21239.91243.50259.07
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity560.43503.23515.63635.59625.32620.35
Total Shareholders Equity560.43503.23515.63635.59625.32620.35
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity560.43503.23515.63635.59625.32620.35
Total Liabilities & Stockholders Equity770.50724.96736.85875.50868.81879.42
Book Value Per Share7.506.776.968.848.768.70
Tangible Book Value Per Share7.436.686.868.738.638.54
Full-Time Employees---260--
Price to Book Ratio5.332.311.361.751.350.87
Return on Assets-14.38-20.36-21.01-10.06-14.00-19.89
Return on Equity-19.88-29.07-29.84-14.00-19.61-29.22
Return on Invested Capital5.69-3.38-19.52-0.86-0.77-3.95
Quick Ratio6.546.396.576.255.995.34
Current Ratio6.546.396.576.255.995.34

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income39.44-21.73-128.92-6.65-6.03-30.82
Depreciation2.242.442.572.582.592.65
Other Funds (Non Cash)-10.21-13.5261.65-55.77-47.53-2.09
Funds from Operations31.46-32.81-64.70-59.84-50.97-30.26
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-28.82-22.85-2.928.1320.15-6.11
Cash from Operating Activities2.64-55.66-67.63-51.71-30.82-36.37
Capital Expenditures-1.80-0.54-0.61-1.14-0.18-0.38
Net Assets From Acquisitions0.000.000.001.730.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments9.1385.6627.2972.3114.8540.86
Purchase of Investments-144.740.00-72.68-37.85-84.23-72.94
Sale Or Maturity of Investments153.8785.6699.97110.1699.09113.80
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities7.3385.1226.6872.9014.6740.48
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock9.991.030.956.320.000.66
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock9.991.030.956.320.000.66
Proceedsfrom Stock Options0.001.000.00-0.660.000.66
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-1.730.000.00
Other Financing Activities Uses0.000.000.00-1.730.000.00
Cash from Financing Activities9.991.030.954.600.000.66
Net Change in Cash19.9630.49-40.0025.78-16.154.77
Free Cash Flow0.84-56.20-68.24-52.85-31.00-36.75

Revenue breakdown

License2024: 8.50M
Milestone2024: 34.50M 2025: 45.30M
Royalty2024: 67.49M 2025: 80.28M
United States2024: 110.49M 2025: 125.58M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3018.26%12.9M70.6M1.49M
2026-10-1517.53%12.3M70.0M1.36M
2026-09-3023.39%16.4M70.0M1.27M
2026-09-1522.51%15.8M70.0M1.20M
2026-08-3121.31%14.9M70.0M1.11M
2026-08-1420.28%14.2M70.0M958.81K
2026-07-3116.21%11.3M70.0M930.32K
2026-07-1515.54%10.8M69.8M817.16K
2026-06-3016.47%11.5M69.9M821.35K
2026-06-1516.11%11.3M69.9M800.51K
2026-05-2915.60%10.9M69.9M833.69K
2026-05-1515.38%10.7M69.6M841.77K
2026-04-3015.12%10.5M69.6M785.94K
2026-04-1514.97%10.3M68.9M774.31K
2026-03-3116.40%11.3M68.9M787.63K
2026-03-1316.28%11.2M68.9M731.55K
2026-02-2716.32%11.2M68.9M691.79K
2026-02-1316.39%11.0M67.1M714.21K
2026-01-3016.28%10.9M67.1M784.81K
2026-01-1515.37%10.3M67.1M969.72K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.5035.5040.000.000.0000.000.000.998-0.0200.000
call5.0033.0037.500.0015.9450.000.000.997-0.0210.001
call7.5030.5035.000.0012.0220.000.000.996-0.0220.001
call10.0028.0031.7015.598.4596.000.000.995-0.0220.001
call12.5025.5029.2012.307.15136.000.000.990-0.0380.002
call15.0023.0026.7011.106.1357.000.000.988-0.0370.002
call17.5020.5024.208.005.3024.000.000.985-0.0370.002
call20.0018.0021.706.214.5946.000.000.931-0.1750.008
call22.5015.5019.207.003.97518.000.000.920-0.1700.009
call25.0013.0016.8015.613.5006,2398.000.906-0.1630.010
call30.009.2010.6010.131.6675,9700.000.868-0.1460.013
call35.004.007.105.581.78219711.000.711-0.2740.021
call40.001.755.002.752.0221,3982.000.557-0.2580.025
call45.000.104.901.202.7245.000.000.474-0.3830.025
call50.000.005.000.003.2830.000.000.428-0.4550.024
put2.500.000.050.008.4670.000.00-0.004-0.0300.001
put5.000.001.350.005.9300.000.00-0.003-0.0210.001
put7.500.000.600.054.76391.000.00-0.004-0.0210.001
put10.000.000.050.104.29810.000.00-0.009-0.0350.001
put12.500.001.351.003.7002.000.00-0.010-0.0360.002
put15.000.000.200.002.9610.000.00-0.013-0.0320.002
put17.500.000.100.152.52515.000.00-0.015-0.0310.002
put20.000.002.300.083.72448.000.00-0.069-0.1730.008
put22.500.001.000.513.2031640.00-0.080-0.1670.009
put25.000.000.900.202.5475,5630.00-0.097-0.1430.011
put30.000.001.303.091.9081380.00-0.132-0.1430.013
put35.000.003.101.292.2621.000.00-0.289-0.2700.021
put40.001.604.102.451.6591.0015.00-0.443-0.2530.025
put45.004.308.000.001.9550.000.00-0.526-0.3780.025
put50.008.0012.500.002.2740.000.00-0.572-0.4490.024

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10144Filing for proposed sale of securities under Rule 144.SEC
2026-11-06SCHEDULE 13G/ASEC
2026-11-05SCHEDULE 13G/ASEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-10-30SCHEDULE 13G/ASEC
2026-10-27SCHEDULE 13G/ASEC
2026-10-268-KCurrent report2026-10-25SEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-31SCHEDULE 13GSEC
2026-07-298-KCurrent report2026-07-29SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-18144Filing for proposed sale of securities under Rule 144.SEC
2026-06-188-KCurrent report2026-06-16SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-15144Filing for proposed sale of securities under Rule 144.SEC
2026-06-15144Filing for proposed sale of securities under Rule 144.SEC
2026-06-15144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-0600379.13K5
2026-050000
2026-040042.99K1
2026-0300527.97K10
2026-020000
2026-010000
2025-12002.95M2
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.18.41%
PRIMECAP MANAGEMENT CO/CA/13.73%
BVF INC/IL9.62%
RTW INVESTMENTS, LP9.14%
RA CAPITAL MANAGEMENT, L.P.7.11%
STATE STREET CORP6.68%
VANGUARD CAPITAL MANAGEMENT LLC4.42%
TCG Crossover Management, LLC3.31%
PRICE T ROWE ASSOCIATES INC /MD/3.18%
VANGUARD PORTFOLIO MANAGEMENT LLC2.99%

Funds

Fund% owned
PRIMECAP Odyssey Aggressive Growth Fund8.54%
iShares Core S&P Small-Cap ETF6.01%
PRIMECAP Odyssey Growth Fund4.18%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.16%
State Street(R) SPDR(R) S&P(R) Biotech ETF2.62%
iShares Russell 2000 ETF2.45%
VANGUARD EXTENDED MARKET INDEX FUND1.16%
Fidelity Small Cap Index Fund1.03%
State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF0.92%
iShares Russell 2000 Value ETF0.87%

OakChart. XNCR. Cached 15 minutes.